Loading stock data…
SANOFI (SAN.PA)
€74.70-0.99 (-1.31%)
Market ClosedLast close Sep 8
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at €74.70 with a market capitalization of $90.3B. Wall Street consensus targets €94.28 (23 analysts), implying a +26.2% move over the next 12 months. The stock is currently near its 52-week low of €71.25, remaining 2.0% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +26.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (EUR) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | €10.73B↓ | €13.17B↑ | €12.21B↑ | €11.24B↓ | €12.30B |
| Gross Profit | €7.74B↓ | €9.76B↑ | €8.45B↑ | €8.11B↓ | €9.28B |
| Operating Income | €1.71B↓ | €3.79B↑ | €1.63B↓ | €2.27B↓ | €2.38B |
| Net Income | €3.94B↑ | €2.80B↑ | -€801.00M↓ | €1.61B↑ | €343.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€90.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.27
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
545.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.71%
Volume
Today's trading volume
1.47M
Recent News
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...
Novartis stock rises after MS drug remibrutinib trial results
The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both studies
Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry
Novartis stock surged Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.
Novartis Reports 3 Patient Deaths. Why the Stock Is Heading for Its Best Day Since 2023.
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.